Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Schizophrenia

    Texas

    Search
    Schizophrenia
    Texas
    Show Map
    Map View
    Texas
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      41 Schizophrenia Trials near Texas

      Power is an online platform that helps thousands of Schizophrenia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Lumateperone for Schizophrenia

      Shreveport, Louisiana
      This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician - Apathy) assessment and to examine a possible correlation between improvement in apathy scores and changes in elements of the PANSS (Positive and Negative Syndrome Scale) due to treatment with Lumateperone.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Dementia, Parkinson's, Others
      Must Not Be Taking:Multiple Antipsychotics, Injectables

      80 Participants Needed

      KarXT for Schizophrenia

      Richardson, Texas
      This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.
      Stay on current meds
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Suicidal Behavior, Pregnant, Urinary Retention, Others
      Must Be Taking:Antipsychotics

      280 Participants Needed

      NBI-1117568 for Schizophrenia

      Austin, Texas
      This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Unstable Condition, Others
      Must Not Be Taking:Antipsychotics

      800 Participants Needed

      NBI-1117568 for Schizophrenia

      Austin, Texas
      The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Unstable Condition, Others
      Must Not Be Taking:Antipsychotics

      284 Participants Needed

      Iloperidone for Schizophrenia

      Richardson, Texas
      The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Other Psychiatric Disorders, Others
      Must Be Taking:Iloperidone

      400 Participants Needed

      SEP-363856 for Schizophrenia

      Richardson, Texas
      Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Alcohol Use, Substance Use, Bipolar, Others
      Must Be Taking:Antipsychotics

      522 Participants Needed

      Digital Therapeutics for Schizophrenia

      Fort Worth, Texas
      This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Other DSM-5 Diagnoses, Others
      Must Be Taking:Antipsychotics

      432 Participants Needed

      OLZ/SAM vs. Olanzapine for Schizophrenia or Bipolar Disorder

      Frisco, Texas
      To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Major Depressive Episode, Seizure Disorder, Diabetes, Others
      Must Be Taking:Antipsychotics

      220 Participants Needed

      Valbenazine for Schizophrenia

      Dallas, Texas
      The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Depression, Substance Use, Others
      Must Be Taking:Antipsychotics

      442 Participants Needed

      OLZ/SAM for Schizophrenia

      Fort Worth, Texas
      This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Suicide Risk, Pregnancy, Others
      Must Be Taking:OLZ/SAM

      236 Participants Needed

      Brexpiprazole for Adolescent Schizophrenia

      Frisco, Texas
      To further characterize the long-term safety and tolerability of brexpiprazole in adolescents with schizophrenia
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:13 - 17

      Key Eligibility Criteria

      Disqualifiers:Delirium, Dementia, Amnesia, Others
      Must Be Taking:Antipsychotics

      295 Participants Needed

      Xanomeline/Trospium for Schizophrenia

      Richmond, Texas
      This is an open label study of the treatment satisfaction, efficacy and tolerability of xanomeline/ trospium in a population of 172 participants diagnosed with schizophrenia in the early phase of illness. Participants will be followed for 24 weeks with scheduled assessments conducted by centralized raters, local mental health professionals and self-assessments completed by patients. Recruitment will be based on insufficient efficacy of previous antipsychotic or due to dissatisfaction with treatment as a result of unacceptable side effects on previous antipsychotic/patient choice, with approximately 50% for each enrollment criteria. Participants who present with both insufficient efficacy and unacceptable side effects will be considered as belonging to the insufficient efficacy subgroup. Treatment and assessments will be identical for the 2 groups. Primary outcome for participants enrolled will be improvement in overall treatment satisfaction as measured by the MSQ.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4
      Age:18 - 40

      Key Eligibility Criteria

      Disqualifiers:Substance Abuse, Cardiovascular, Glaucoma, Others
      Must Be Taking:Antipsychotics

      172 Participants Needed

      KarXT for Schizophrenia

      DeSoto, Texas
      The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:New Schizophrenia, Alcohol, Drug Use, Others
      Must Not Be Taking:Antipsychotics

      60 Participants Needed

      Iloperidone Safety for Adolescent Schizophrenia

      DeSoto, Texas
      To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Others
      Must Not Be Taking:Investigational Drugs, Drugs Of Abuse

      100 Participants Needed

      KYN-5356 for Schizophrenia

      Austin, Texas
      This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days. Participants will be randomized to one of 4 treatment groups: placebo, KYN-5356 low dose, KYN-5356 medium dose, KYN-5356 high dose. Participants will be admitted to the clinic on Day -3 and will remain in residence at the clinic for 32 days, from baseline through the treatment period. Participants will be administered investigational medicinal product on Days 1 through 28. Efficacy, safety, PK and exploratory PD assessments will be performed throughout the dosing period. Participants will be discharged on Day 29 after safety assessments are completed and return for a follow-up visit on Day 42. A subset of participants from selected sites will undergo electrophysiological assessments to evaluate the effect of KYN-5356 on neurophysiological measures of brain function.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Unstable Condition, Others
      Must Be Taking:Antipsychotics

      150 Participants Needed

      LB-102 for Schizophrenia

      Richardson, Texas
      This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S, safety and tolerability, and pharmacokinetics.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      350 Participants Needed

      Ocrelizumab for Psychosis

      Houston, Texas
      Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly fire." Auto-antibodies attack brain receptors and then the person who has this problem begins to have hallucinations and other manifestations of schizophrenia, like feeling that people can see what they are thinking and also feeling that other people do not like them. If this disease is caused by auto-antibodies, typically the person is well until they are 15 years of age or older, but seldom older than 35 years. Then, in a matter of a few months they begin to have hallucinations and the other symptoms. Doctors still do not know whether some people with schizophrenia or bipolar disease have auto-antibodies attacking their brain. For this reason, in this study some of these patients will receive a treatment that suppresses the auto-antibodies and their symptoms after treatment will be compared with the symptoms of a group of similar patients who are given a preparation that looks like the real treatment, but it is not.
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:18 - 35

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Cancer, Severe Cardiovascular, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      40 Participants Needed

      Emraclidine for Schizophrenia

      Richardson, Texas
      Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 258 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Other DSM-5 Disorders, Treatment Resistance, Others
      Must Not Be Taking:Clozapine

      258 Participants Needed

      ML-007C-MA for Schizophrenia

      Richardson, Texas
      ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 64

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Others
      Must Not Be Taking:Antipsychotics

      300 Participants Needed

      Emraclidine for Schizophrenia

      Oklahoma City, Oklahoma
      This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Cardiovascular, Diabetes, Others
      Must Be Taking:Antipsychotics

      850 Participants Needed

      Why Other Patients Applied

      "My psychosis has been manageable for the past few years since I found an antipsychotic that works okay but I still struggle with a lot of mind fog and memory issues. I haven't heard of a treatment for those symptoms until learning about new research so I'm hoping to join a trial to get access."

      AQ
      Schizophrenia PatientAge: 40

      "I'm willing to try anything to help improve and manage my schizophrenia in any way. I do my best each day to keep the hallucinations at bay. I no longer hear voices but I don't want them to come back either. Most medicine I've tried hasn't help very much."

      ZC
      Schizophrenia PatientAge: 39

      "I would like to get a medication that has fewer side effects than the ones I've used. Many antipsychotics just make me numb or flat and I can't really think. Also I like the idea of helping in research to find better medications for schizephrenia."

      VT
      Schizophrenia PatientAge: 60

      "I've tried many medications that didn't work that well. I really really want to be better and function in society... a different kind of treatment could help."

      FF
      Schizophrenia PatientAge: 36

      "I’ve been diagnosed with Schizoaffective Disorder for over 5 years now and not found much relief in medication. One I’ve tried helped a bit but the side affects were overwhelming. Hoping I can gain some relief from this disorder and help advance research as well!"

      MX
      Schizophrenia PatientAge: 44
      Match to a Schizophrenia Trial

      BXCL501 for Pediatric Schizophrenia and Bipolar Agitation

      DeSoto, Texas
      This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Acute Intoxication, Suicide Risk, Others
      Must Not Be Taking:Benzodiazepines, Hypnotics, Antipsychotics

      140 Participants Needed

      KarXT for Schizophrenia

      Austin, Texas
      The purpose of this study is to evaluate the dose levels, safety, and drug levels of KarXT intramuscular injection in participants with Schizophrenia
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:New Schizophrenia, Major Depression, Others
      Must Not Be Taking:Antipsychotics

      48 Participants Needed

      rTMS for Depression in Schizophrenia

      Houston, Texas
      The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia. Schizophrenia patients with depressive symptoms will be exposed to rTMS to improve their symptoms.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Stroke, Seizure, Head Trauma, Others

      120 Participants Needed

      Neuromodulation for Schizophrenia

      Houston, Texas
      Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil combined with cognitive training for improving white matter integrity.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Seizures, Stroke, Substance Abuse, Others
      Must Not Be Taking:Clozapine

      120 Participants Needed

      Magnetic Stimulation for Schizophrenia

      Houston, Texas
      Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Seizures, Unstable Medical Illnesses, Alcohol/drug Use, Others
      Must Not Be Taking:Clozapine

      120 Participants Needed

      Deep Brain Stimulation for Schizophrenia

      Dallas, Texas
      There are three hypotheses proposed for this study: 1) Participants will report no unanticipated serious adverse events during the eight months of treatment. 2) Investigators will successfully model psychotic versus non-psychotic brain states using support vector machine (SVM) classifiers. 3) Participants specific brain stimulation parameters can induce a change in the brain state consistent with non-psychotic states as measured by classifier output. Hypotheses 1, 2, and 3 address safety and tolerability, efficacy, and the putative mechanism of successful treatment. The overall objective is to use next generation Deep Brain Stimulation (DBS) combined with antecedent stereo electroencephalogram (SEEG) mapping to establish a new therapy for treatment-refractory schizophrenia given the limitations of current treatment modalities. The primary objective is to demonstrate safety of acute and chronic network guided stimulation for treatment-refractory schizophrenia. Exploratory Objectives: 1. Use intracranial mapping (SEEG) combined with pharmacological manipulation of psychotic states to create a protocol for participant specific deep brain stimulation to treat treatment-refractory schizophrenia. 2. Develop closed loop stimulation protocols to modify brain states during psychotic brain activity induced by low-dose ketamine administration. 3. Investigate the use of mnemonic similarity to characterize brain networks related to symptoms of treatment-refractory schizophrenia. 4. Treatment-related objectives: Record a reduction in psychotic symptoms, as well as an improvement in psychosocial function and cognition.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:22 - 70

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Suicidal Risk, Seizure Disorder, Others
      Must Be Taking:Antipsychotics

      10 Participants Needed

      iTEST for Psychotic Disorders

      Richardson, Texas
      This trial tests iTEST, a mobile-based program designed to help people with schizophrenia or schizoaffective disorder improve their self-assessment skills and apply them to daily life. The goal is to reduce disability by enhancing their ability to judge their own abilities accurately.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Dependence, Severe Medical Illness, Others

      60 Participants Needed

      TMS for Smoking Cessation in Schizophrenia

      Houston, Texas
      This trial uses a magnetic pulse device to help people with schizophrenia stop smoking. It targets specific brain areas involved in both conditions. The goal is to see if this method is effective for this particular group. This method has been shown to decrease cigarette consumption in schizophrenia patients.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:22 - 65

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Alcohol, Major Medical Illnesses, Others
      Must Not Be Taking:Cephalosporins, Antiarrhythmics

      50 Participants Needed

      TMS for Schizophrenia

      Houston, Texas
      The purpose of the study is to test the hypothesis that functionally navigated repetitive TMS stimulations to the prefrontal cortex (PFC) modulate aberrant cortical electrical activities at PFC circuitry. The TMS location of the PFC site will be individually localized by the symptom-related functional connectivity between PFC and symptom related areas (such as the auditory and language processing cortex). The investigators predict that such modulation will correct abnormal activities in patients with schizophrenia, reduce symptoms, especially auditory hallucination, and improve working memory/sustained attention performance.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Substance Abuse, Brain Conditions, Others
      Must Be Taking:Antipsychotics

      140 Participants Needed

      KarXT for Schizophrenia

      Irving, Texas
      This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Treatment-resistant Schizophrenia, Severe Medical Conditions, Others
      Must Be Taking:Atypical Antipsychotics

      360 Participants Needed

      12

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Flu Clinical Trials

      Top Clinical Trials near Elkins Park, PA

      Top Hot Flashes Clinical Trials

      28 Bipolar Disorder Trials near Los Angeles, CA

      Top Hemophilia A Clinical Trials

      14 Osteoporosis Trials near New York, NY

      Top Clinical Trials near Columbia, MO

      Top Clinical Trials near Emeryville, CA

      38 Retinitis Pigmentosa Trials near Miami, FL

      Top Bronchiolitis Obliterans Clinical Trials

      Top Amyotrophic Lateral Sclerosis Clinical Trials

      Top Clinical Trials near Hayward, WI

      By Trial

      PrimeTaper EV Implant for Missing Teeth Restoration

      Percussion Therapy for Muscle Pain

      Isunakinra + Pembrolizumab for Colorectal Cancer

      Skin Substitutes + Standard Care for Diabetic Foot Ulcers

      Radiation Therapy for Non-Hodgkin's Lymphoma

      Watermelon Juice for Heart Rate Recovery and Muscle Pain

      Cordella™ Sensor System for Heart Failure

      Family Navigator Plus for Families

      CirrhosisRx CDS for Liver Cirrhosis

      Psilocybin for OCD

      Satralizumab for Duchenne Muscular Dystrophy

      Glutamine Metabolism Assessment in Healthy Subjects

      Frequently Asked Questions

      How much do Schizophrenia clinical trials in Texas pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Schizophrenia clinical trials in Texas work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Schizophrenia trials in Texas 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Texas for Schizophrenia is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Texas several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Schizophrenia medical study in Texas?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Schizophrenia clinical trials in Texas?

      Most recently, we added KarXT for Schizophrenia, Lifestyle Program for Diabetes in People with Serious Mental Illness and KarXT for Schizophrenia to the Power online platform.

      Why is schizophrenia more common now?

      Most studies show the yearly number of new schizophrenia cases hasn’t skyrocketed; it only feels more common because doctors now catch milder cases and people with the illness live longer, so more are counted at any one time. Modern lifestyle changes—growing up in crowded cities, high-potency cannabis use, migration stress, older parenthood, and ongoing poverty—do add modest risk for certain groups, nudging overall figures upward. Recognising these drivers guides prevention efforts like early screening, substance-use education, urban social support, and good prenatal care.

      What is the best injection for schizophrenia?

      There isn’t one “best” injection for everyone with schizophrenia. Doctors usually choose among long-acting injectables such as paliperidone (monthly to every 6 months), aripiprazole (monthly or every 2–3 months) or risperidone (every 2 weeks to monthly) based on which oral version has helped you before, how often you can come for shots, and which side-effects you’re most sensitive to. Your psychiatrist will review these factors—plus cost, other health conditions and personal preference—to decide which LAI is the safest and most effective fit for you.

      Who is most likely to recover from schizophrenia?

      Research shows the best odds of meaningful recovery occur in people who get treatment quickly after their first symptoms, keep taking medication and using psychological/rehab supports, avoid alcohol or drugs, and have steady family or community support; women and those whose illness starts later in their 20s also tend to fare somewhat better, but these fixed factors matter less than the modifiable ones above. In short, while anyone with schizophrenia can improve, the combination of early intervention, sticking with care, healthy lifestyle, and strong social ties makes the biggest difference in who recovers.

      Is schizophrenia inherited from mother or father?

      Schizophrenia risk is passed down through many genes that you receive from both parents, and large studies do not show a consistent advantage of either the mother’s or the father’s side. Compared with the 1 % lifetime risk in the general population, the chance rises to about 10 % if one parent has schizophrenia and up to 40 % if both do; factors such as pregnancy complications, cannabis use, severe stress, or very advanced paternal age can add to that risk. Families with a history of the illness may benefit from genetic counselling and early mental-health check-ups during adolescence so any warning signs can be managed promptly.

      How is schizophrenia viewed in China?

      China does not have a single view of schizophrenia: in big cities many people now regard it as a treatable brain disorder, but in rural areas it may still be linked to spirit possession or seen as a source of family “shame,” so relatives often hide the illness and shoulder most care. High stigma persists because unusual behaviour is felt to threaten the family’s “face,” yet government programs such as the nationwide 686 follow-up system and the 2013 Mental-Health Law are expanding hospital care, community visits, and public education. Overall, attitudes are gradually shifting toward acceptance, but progress is uneven and support for both patients and their families remains a work in progress.

      Are there any clinical trials being done for schizophrenia?

      Yes—dozens of studies are actively recruiting worldwide, ranging from novel medicines like KarXT (muscarinic M1/M4 agonist), ulotaront (TAAR1 agonist), and roluperidone (aimed at negative symptoms) to long-acting weekly risperidone implants (TV-46000) and app-based cognitive programs. You can see real-time listings, eligibility criteria, and locations by typing “schizophrenia” into ClinicalTrials.gov or the EU Clinical Trials Register and then reviewing the options with your psychiatrist to weigh potential benefits, risks, and travel demands.

      What is the biggest problem of schizophrenia?

      Schizophrenia isn’t defined by one “biggest problem”; clinicians group its effects into positive symptoms (hallucinations/delusions), disorganization, negative symptoms (loss of drive, social withdrawal) and cognitive deficits. Studies show that after acute psychosis is controlled, the lasting obstacles to working, studying and maintaining relationships are usually the negative and cognitive symptoms, so effective care pairs antipsychotic medication with therapies and skills training that rebuild motivation, thinking and daily-living abilities.

      Who has the highest rate of schizophrenia?

      Worldwide, the single highest recorded rates occur in young adult Black Caribbean or Black African men who are migrants (or children of migrants) living in large urban areas; their chance of developing schizophrenia can be 4- to 9-times higher than that of white native-born residents. In general, men have a modestly higher risk than women (about 1.4 : 1), but factors such as minority or migrant status and growing up in a high-density city raise risk far more than sex alone.

      What's the latest schizophrenia can develop?

      Most people who develop schizophrenia do so between their late teens and early 30s, but experts recognise “late-onset” cases appearing at 40-60 and a rarer “very-late-onset schizophrenia-like psychosis” beginning after 60. Because psychosis this late in life is uncommon and can mimic problems such as dementia, stroke, or severe depression, anyone with new hallucinations or delusions at these ages should be evaluated promptly by a mental-health professional and a physician to sort out the cause and start the right treatment.